Zlabinger G J, Stuhlmeier K M, Eher R, Schmaldienst S, Klauser R, Vychytil A, Watschinger B, Traindl O, Kovarik J, Pohanka E
Institute of Immunology, University of Vienna, Austria.
J Clin Immunol. 1992 May;12(3):170-7. doi: 10.1007/BF00918085.
Cytokine release and clinical side effects resulting from the use of OKT3 and BMA 031 monoclonal antibodies in the treatment of kidney graft recipients were evaluated and compared. The rise observed in serum levels of interferon gamma. TNF alpha, and IL-8 was similar after administration of either monoclonal antibody. Furthermore, both OKT3 and BMA 031 resulted in rapid disappearance not only of virtually all T cells, but also of substantial percentages of all major leukocyte populations from the circulation; this effect is probably due to cytokine release activating endothelial cells and thereby causing extravasation even of leukocytes not specifically recognized by the administered antibodies. Evidence has thus been obtained that BMA 031 is as potent as OKT3 in inducing unequivocal signs of T cell activation in vivo. However, while OKT3 therapy was accompanied by adverse side effects in our study as in previous ones, we saw no such reactions in any of the patients receiving BMA 031. This contrast might be due to different mechanisms of leukocyte activation possibly inducing other mediators in the case of OKT3, which then, in combination with the cytokines, could generate treatment-associated morbidity.
评估并比较了在肾移植受者治疗中使用OKT3和BMA 031单克隆抗体所导致的细胞因子释放及临床副作用。给予任何一种单克隆抗体后，血清中γ干扰素、肿瘤坏死因子α和白细胞介素-8水平的升高情况相似。此外，OKT3和BMA 031不仅导致几乎所有T细胞迅速消失，还使循环中所有主要白细胞群体的相当比例消失；这种效应可能是由于细胞因子释放激活了内皮细胞，从而导致即使是未被所给抗体特异性识别的白细胞也发生外渗。因此，已有证据表明BMA 031在体内诱导明确的T细胞激活迹象方面与OKT3一样有效。然而，在我们的研究中，与之前的研究一样，OKT3治疗伴有不良副作用，而在接受BMA 031治疗的任何患者中我们都未观察到此类反应。这种差异可能是由于白细胞激活机制不同，在OKT3的情况下可能诱导其他介质，然后这些介质与细胞因子一起可能产生与治疗相关的发病率。
